The information provided here is for informational purposes only
Unresolved safety questions The staff review identified uncertainty about immunogenicity, aggregation, peptide-related impurities, hypersensitivity, route-specific risk, repeated exposure, and long-term use
Dec 29, 2025 Cagrilintide is a long-acting amylin receptor agonist that produces 10-12% body weight loss through mechanisms completely different from GLP-1s - dramatically slowing gastric emptying, suppressing appetite via brain amylin receptors, and reducing postprandial glucose
Some may experience minor side effects such as: Redness or swelling at the injection site Temporary soreness or bruising Less commonly, side effects could include: Mild headaches Nausea Itchy skin or rash Should you notice any prolonged side effects, we recommend speaking with your GP or calling NHS 111 for advice
The intestinal barrier must decide what to do with all these things
Resolution: Weeks 1-2 Neurotransmitter receptors recalibrate